Walleye Capital
TVRD

Walleye Capital’s Tvardi Therapeutics TVRD Stock Holding History

Walleye Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-114
Closed -$80K – 2129
2019
Q1 		$80K Buy
+114
New +$68.2K 0.01% 1104

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's TVRD Position: Q4 2023 in Review

Walleye Capital sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 3,806 shares — an estimated $230K sold.

Walleye Capital first reported a position in TVRD in Q4 2019 and held it in 4 quarters. The position peaked at $397K in Q2 2023. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Walleye Capital reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Walleye Capital sold 3,806 Tvardi Therapeutics shares in Q4 2023, an estimated $230K.
  • Walleye Capital first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 4 quarters.
  • Walleye Capital's Tvardi Therapeutics position peaked at $397K in Q2 2023.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.